Nelotanserin Completed Phase 2 Trials for Primary Insomnia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00664664Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia